Summary: Avadel Pharmaceuticals plc announced the publication of final data from the RESTORE open-label/switch study, which demonstrated a strong preference among people with narcolepsy for the once-nightly Lumryz over a twice-nightly immediate-release oxybate. Lumryz, approved … [Read more...]
Avadel Eyes New Indications for Narcolepsy Drug Lumryz
Summary: Avadel Pharmaceuticals announced its second-quarter results, highlighting the progress of its narcolepsy drug, Lumryz. The company initiated a phase 3 trial for Lumryz in idiopathic hypersomnia and awaits an FDA decision on its use in pediatric narcolepsy. Lumryz, … [Read more...]
First Patient Dosed in Phase 3 Study of Lumryz for IH
Summary: Avadel Pharmaceuticals has commenced dosing in the REVITALYZ phase 3 study to evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a treatment for idiopathic hypersomnia (IH). The study, involving approximately 150 adults, aims to assess the … [Read more...]
Avadel to Present Data on Lumryz for Narcolepsy at SLEEP 2024
Summary: At Sleep 2024, Avadel will present new data on Lumryz, the initially extended-launch, when-nightly formulation of sodium oxybate for narcolepsy. Findings highlighted client preference for Lumryz around twice-nightly oxybate, with 94% preferring when-nightly dosing and … [Read more...]
Avadel Reports Uptick in Lumryz Therapy Adoption for Narcolepsy
Summary: Avadel Prescription drugs reported a considerable improve in Lumryz use for narcolepsy, with around 1,700 individuals initiating therapy—a 70% rise considering the fact that December. The enterprise is searching to expand Lumryz’s indications into pediatric treatment … [Read more...]